| This week's sponsor is Optum. | |  | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Friday, December 7, 2018 What does it take for a company to attract millennials? An inspiring and empowering culture, according to Novartis CEO Vas Narasimhan, and he's starting by loosening the dress code. Yes, even at the company's Basel headquarters. |
|
|
| This week's sponsor is FierceBiotech. | |  | |
Top Stories Of The Week Friday, December 7, 2018 AstraZeneca’s tremelimumab has come up short in another phase 3 trial. Having failed to improve outcomes in metastatic non-small cell lung cancer, the anti-CTLA4 antibody has now missed the primary endpoint in a phase 3 advanced head and neck cancer trial. Friday, December 7, 2018 Moderna’s IPO always looked like a record breaker for biotech and came in even larger than expected at $604 million, valuing the company at an eye-watering $7.9 billion. Tuesday, December 11, 2018 Merck & Co. boasted some major success in the sales department this year, but the company’s commercial organization will still get a makeover for 2019. Adam Schechter, president of global human health, will leave on Dec. 31, triggering an executive shake-up. Friday, December 7, 2018 Merck’s Keytruda finally has some immuno-oncology competition in first-line, non-small cell lung cancer, courtesy of Roche. But even with an FDA approval in the bag, the real test for Roche might still be to come. Friday, December 7, 2018 The ability to regenerate insulin-producing cells in the pancreas would do the job, but that has so far proven to be an elusive target. A team of Stanford University scientists is now searching for a solution in a common nutrient: zinc. Wednesday, December 12, 2018 If you can’t beat 'em, join 'em: Roche is teaming up with its immuno-oncology competitor Merck & Co. to develop a pan-cancer companion diagnostic test for its Keytruda therapy aimed at detecting the mismatch repair deficiency biomarker, or dMMR, in solid tumors regardless of their location. Wednesday, December 12, 2018 Since Pfizer’s Kansas plant received an FDA warning letter last year, the company has insisted it is making good progress on turning things around at the essential but troubled injectables facility. But the findings from the most recent inspection show problems persist, and most of them the FDA had flagged before. Tuesday, December 11, 2018 More than 40,000 people have received Merck & Co.’s Ebola vaccine in the latest outbreak—the second-largest ever—but experts are still calling on the U.S. to send back CDC specialists to help contain it. Wednesday, December 12, 2018 New York-based tech CRO TrialSpark launched its first clinical trial sites as part of a partnership with Novartis that takes a new direction. Resources Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
